MonoMethyl auristatin E is primarily used as a potent cytotoxic agent in the development of antibody-drug conjugates (ADCs). These ADCs are designed to target and deliver the drug specifically to cancer cells, minimizing damage to healthy tissues. The chemical works by inhibiting tubulin polymerization, which disrupts cell division and leads to cancer cell death. Its high potency makes it particularly effective in treating various cancers, including lymphoma, breast cancer, and ovarian cancer, when conjugated to tumor-specific antibodies. This targeted approach enhances therapeutic efficacy while reducing systemic toxicity.